INTESTINE Vol.22 No.5(9)


特集名 大腸腫瘍の分子生物学
題名 分子生物学から見た大腸腫瘍─課題と将来展望
発刊年月 2018年 09月
著者 三代 雅明 大阪大学大学院医学系研究科消化器外科学
著者 水島 恒和 大阪大学大学院医学系研究科消化器外科学
著者 土岐 祐一郎 大阪大学大学院医学系研究科消化器外科学
著者 森 正樹 大阪大学大学院医学系研究科消化器外科学
【 要旨 】 次世代シークエンサーの登場を契機とした遺伝子解析技術の飛躍的な向上により,新たな大腸癌サブタイプ分類(CMS)が提唱され注目を集めている.遺伝子検査の倫理的問題・遺伝子情報のセキュリティ・遺伝子解析手法の標準化などの解決すべき問題は残されてはいるが,サブタイピングに基づくprecision medicineによる個別化医療への流れは今後より強まっていくものと思われる.
Theme Molecular biology of colorectal tumors
Title Colorectal tumor from the viewpoint of molecular biology-issues and future prospects
Author Masaaki Miyo Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine
Author Tsunekazu Mizushima Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine
Author Yuichiro Doki Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine
Author Masaki Mori Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine
[ Summary ] The introduction of next generation sequencing for clinical samples and molecular pre-screening programs including circulating tumour DNA analyses with major advances in preclinical models meant that investigators have been able to characterize patterns of co-occurring driver events. They have also been able to identify novel, rare, targetable alterations with potentially higher oncogenic dependency, understand the dynamics of target inhibition to design more rational drug combinations and recognize that temporal heterogeneity and clonal selection can explain resistance to matched targeted agents in colorectal cancer (CRC). Thanks to these dramatic improvements in gene analysis technology, colorectal cancers can be divided into four gene expression categories based on biologically distinct consensus molecular subtypes (CMS). CMS from CRC is expected to provide clinicians with informal concerning prognoses, therapeutic responses, and potential novel therapeutic strategies. However, CMS usage presents some problems including ethical issues for genetic examination, security of genetic information and necessity of a unified approach for genetic analyses. Precision medicine for CRC based on CMS must be developed.
戻る